WPA
PVCT

Wealth Preservation Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Wealth Preservation Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.68K Hold
52,600
– – ﹤0.01% 560
2025
Q4 		$2.94K Hold
52,600
– – ﹤0.01% 466
2025
Q3 		$4.68K Buy
52,600
+600
+1% +$53 ﹤0.01% 376
2025
Q2 		$3.9K Hold
52,000
– – ﹤0.01% 393
2025
Q1 		$5.2K Buy
+52,000
New +$5.2K ﹤0.01% 374

Other funds holding PVCT

HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return
ACM
Academy Capital Management Waco, Texas $699M AUM 12.08% 1-Year Est. Return
AW
Atlas Wealth Cincinnati, Ohio $701M AUM 15.28% 1-Year Est. Return
FS
Financial Symmetry Raleigh, North Carolina $300M AUM 23.79% 1-Year Est. Return

Wealth Preservation Advisors's PVCT Position: Q1 2026 in Review

Wealth Preservation Advisors held its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) position steady in Q1 2026 at 52,600 shares worth $2.68K. The position accounts for ﹤0.01% of the portfolio, ranked #560.

Wealth Preservation Advisors first reported a position in PVCT in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.2K in Q1 2025. 6 funds tracked by Wall St. Rank hold PVCT as of Q1 2026.

  • Wealth Preservation Advisors held 52,600 shares of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) worth $2.68K as of Q1 2026.
  • Wealth Preservation Advisors left its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) share count unchanged in Q1 2026.
  • PROVECTUS BIOPHARMACEUTICALS, INC. (DE) made up ﹤0.01% of Wealth Preservation Advisors's portfolio in Q1 2026, its #560 holding.
  • Wealth Preservation Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q1 2025 and has held it in 5 quarters since.
  • Wealth Preservation Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $5.2K in Q1 2025.
  • 6 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q1 2026.

Based on Wealth Preservation Advisors's 13F filing for Q1 2026, filed 15 May 2026.